Connect with us

Science & Technology

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

Published

on

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that Dr. Scott T. Tagawa, M.D., M.S., FACP, a Professor of Medicine and Urology at Weill Cornell Medicine and an Attending Physician at New York-Presbyterian-Weill Cornell Medical Center, has joined the Company’s Scientific Advisory Board.

(PRNewsfoto/AIkido Pharma Incorporated)

“Scott is a leading scholar in the field of oncology medicine and research,” commented Mr. Anthony Hayes, CEO of AIkido. “His experience and expertise will be of tremendous value as we further our efforts to develop therapeutic treatments for cancer and leverage the technologies we have licensed. Dr. Tagawa is also the principle investigator for the targeted radiopharmaceutical therapy at Weil Cornell and his addition to our advisory board demonstrates our support for this innovative technology.”

Dr. Scott T. Tagawa, MD, MS, FACP is a Professor of Medicine & Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center. Dr. Tagawa earned his BS from Georgetown University. He received his MD at the University of Southern California School of Medicine and after completing his internship and residency training there, he became Chief Resident. Subsequently, he underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years.

 

In August 2005, Dr. Tagawa was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials.

Dr. Tagawa was recruited to Weill Cornell Medical College in 2007. His research covers clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer. Dr. Tagawa also serves as Associate Director of Clinical Research for the Division of Hematology and Medical Oncology and leader of the Genitourinary Disease Management Team of the Meyer Cancer Center. Dr. Tagawa is the WCMC principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. He is a member of the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology (ASCO).

Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies and has been named on multiple “top doctor” award lists.

About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

Continue Reading
Advertisement

Science & Technology

AIkido Pharma Adds Inventor Dr. Neil H. Bander, M.D. to Scientific Advisory Board

Published

on

By

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that Dr. Neil H. Bander, M.D., a physician-researcher at Weill Cornell Medicine, has joined the Company’s Scientific Advisory Board.

(PRNewsfoto/AIkido Pharma Incorporated)

“Dr. Bander heads one of the world’s most experienced and accomplished teams in antibody-targeted therapy of prostate cancer at Cornell University and is a widely respected inventor of patented technologies and recognized expert in the field of urological oncology,” commented Mr. Anthony Hayes, CEO of AIkido. “Importantly, Dr. Bander is the inventor of targeted radiopharmaceutical therapy technology at Convergent Therapeutics, Inc. which we are proud to support. We are honored to have him join our team of advisors and work more directly in our efforts to advance the development of this technology.”

 

“Using his clinical background and laboratory efforts, Dr. Bander has exemplified the role of surgeon-scientist,” added Mr. Hayes. “His research has spawned novel clinical trials that are unique in urological oncology and have already made a difference in the lives of prostate cancer patients. We look forward to leveraging his expertise as we continue to develop our platforms and forge a path towards the treatment of cancer.”

Dr. Bander, M.D. completed fellowship training in both tumor immunology and urological oncology at Memorial Sloan-Kettering Cancer Center in New York City. Subsequently, at New York-Presbyterian Hospital-Weill Cornell Medical Center (NYPH/WCM), where he is the Bernard and Josephine Chaus Professor of Urologic Oncology, he has focused on clinical urological oncology and the development of monoclonal antibodies for targeted cancer therapy. As a result of his efforts, his research group developed the first antibodies to prostate-specific membrane antigen (PSMA) that could effectively bind prostate cancer cells. As a result of his efforts, PSMA is now recognized as the most prostate-cancer specific cell surface antigen known and is the target of a wide variety of anti-cancer technologies. The NYPH/WCM Uro-Oncology research team has sponsored more than 15 clinical trials with anti-PSMA antibodies and more recently, small molecule PSMA agents, in prostate cancer patients with more than 500 patients treated in these trials.

Dr. Bander said, “I look forward to joining my Weill-Cornell colleague, Dr. Scott Tagawa, on AIkido’s SAB, as well as the other AIkido team members, to generate advances that make an impactful difference in the lives of cancer patients.”

About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

Continue Reading

Science & Technology

Territory Mapping Company Educate On Optimizing Sales Territories

Published

on

By

Wake Forest, North Carolina (findit ) January 6, 2021 – Geographic Enterprises have recently released a new educational resource that focuses on explaining how to properly optimize sales territories. The new article is guided by the experts at Geographic Enterprises who have helped businesses properly organize and optimize their sales processes through sales territory mapping and other mapping solutions. They hope this new article will help readers understand how to better optimize different sales territories.

Geographic Enterprises offers readers some valuable information on how to properly optimize sales territories and how professionals approach this process. In the article, they provide some helpful tips that include organizing sales territories geographically, prioritizing territories based on their value, reviewing demographics of key areas, identifying patterns in sales across different regions, and more. The team at Geographic Enterprises takes pride in helping offer a proven method that can help improve stale numbers and give sales teams a new way to approach sales territory organization and optimization.

While this new article focuses on explaining some of the methods they employ in their sales mapping strategies, Geographic Enterprises’ website also provides readers with more information regarding their team, experience, as well as a full list of service offerings. Geographic Enterprises offers sales territory mapping software that includes cloud-based location data, data visualizations, geographical business intelligence organizations, and more. Geographic Enterprises aims to bridge the gap between businesses looking to optimize their processes and the data that is needed to do so. By utilizing data and mapping software, businesses can successfully identify & target consumer demographics, optimize logistics, and expand sales territories unlike ever before.

With the addition of this new article, the team at Geographic Enterprises hopes that readers will have a better understanding of the value of sales territory mapping software and how it can help improve sales plans and outcomes. For more information, contact Geographic Enterprises today at 919-267-3488 or visit their website at https://mappingresources.com/. Their offices are located at 1400 Flemming House Street in Wake Forest, NC 27587.

###

Continue Reading

Science & Technology

New York City Managed IT Services Provider Educate On RTO & RPO

Published

on

By

Seaglass Technology

New York (Findit) December 02, 2020 – Seaglass Technology, an New York City managed IT service provider, has recently released a new educational resource that focuses on explaining the differences between RTO and RPO. The new article is guided by the managed IT experts at Seaglass who specialize in information technologies and how business owners can prepare for unforeseen data disasters. They hope this new article will help business owners looking for more information about these two plans better understand how they are different from each other.

Seaglass technologies offer readers some valuable information regarding the differences between RTO and RPO disaster recovery processes. In the article, they explain the similar characteristics between these two protocols which include how they are measured, how applications/data expenses are factored in and the implementation of continuous data replication. They also explain how they are different which boils down to one simple point. The team at Seaglass technology hopes that this information will help business owners understand how to differentiate these two important objectives from each other.

While this new article focuses on explaining the differences between RTO and RPO in disaster recovery, Seaglass Technology’s website offers readers more information regarding their team, experience, as well as a full list of service offerings. Seaglass offers managed IT services that include IT help desk services, remote monitoring & management, cloud services, data backup, disaster recovery, network installation, and more. By working with SeaGlass Technology, businesses are able to gain access to business-grade technology, leverage tools that help increase the reliability of their IT infrastructure, and also receive a specialized virtual CIO (vCIO).

With the addition of this new article, Seaglass hopes that readers will have a better understanding of the key differences between RTO and RPO objectives when planning disaster recovery protocols. For more information, contact the managed IT experts at Seaglass today at 212-886-0790 or visit their website at https://www.seaglasstechnology.com/. Their offices are located at 500 7th Avenue, 8th Floor, in New York, NY 10018.

###

Continue Reading

Trending